☰
Contact us

Complete the form below and we'll get back to you shortly.


This website is secure, and we do not share your personal information with any third party. Privacy Policy

404

The report you are viewing has been temporarily removed or its title has been changed. While you're here, let us know your specific needs and we'll do a custom analysis to precisely address your business concerns.

Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.

Category
Quick Links
Office Address
Global PARP Inhibitors Market
☰

Global PARP Inhibitors Market

Report ID : 1383 | Published : 2022-10-04 | Pages: | Format: PDF/EXCEL

Share

The market size of the Global PARP Inhibitors Market in the year 2021 is valued at 6.03 billion and is predicted to reach 16.74 billion by the year 2030 at an 12.35% CAGR during the forecast period.

Poly ADP-Ribose Polymerase (PARP) inhibitors are long chains of 17 enzymes that connect many ADP-ribose units into a chain and transport them to the target proteins. This helps heal DNA when it is damaged by various factors, such as certain anti-cancer drugs and exposure PARP inhibitors prevent an enzyme required for the repair of DNA single-strand breaks. Inhibition of this DNA repair enzyme can lead to cell death, especially in cancer cells lacking alternative DNA repair pathways. These inhibitors are, therefore, frequently used to treat several malignancies, including ovarian and breast cancer. The expectation of PARP inhibitors driving market expansion will rise as the incidence rate of cancer demands novel treatments. The market size may increase as more people become aware of the benefits of using PARP inhibitors to treat cancer. The market will grow due to the rising elderly population and the prevalence of cancer. Another factor influencing the growth of this market is government spending on health care. PARP inhibitor side effects impede market expansion. Another problem limiting market growth is resistance to PARP inhibitors; strict regulatory restrictions will prevent market expansion. The market for poly (ADP-ribose) polymerase (PARP) inhibitors will have a lot of chances in the future due to the growing population and increased knowledge of cancer treatments.

Market Segmentation:

The PARP Inhibitors market is segmented on drug type, indication and distribution channel. Based on drug type, the market is segmented into Olaparib, Niraparib, Rucaparib and Talazoparib. Based on the indication, the PARP Inhibitors are segmented into Ovarian Cancer, Breast Cancer, Prostate Cancer and Pancreatic Cancer. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.

Based on drug type, the Granulocyte–Colony-Stimulating Factor (G-CSF) segment is accounted as a major contributor to the PARP Inhibitors market.

Based on drug type, the market is segmented into Olaparib, Niraparib, Rucaparib and Talazoparib. The olaparib segment dominated the market. Growth in the market is anticipated to be aided by rising product approvals and expanding use of olaparib PARP inhibitors to treat pancreatic, ovarian, and breast cancer. In addition, it is anticipated that the market for niraparib will increase rapidly and make up about one-third of the revenues of PARP inhibitors by 2022.

The prostate cancer segment witnessed growth at a rapid rate.

Based on the indication, the PARP Inhibitors are segmented into Ovarian Cancer, Breast Cancer, Prostate Cancer and Pancreatic Cancer. The prostate cancer segment dominated the market, and the increasing prevalence of prostate cancer worldwide is the main factor promoting market expansion. According to the World Cancer Research Fund, prostate cancer is the second most prevalent type of cancer identified in males and the fourth most common cancer worldwide. Additionally, it is anticipated that growing olaparib use in first-line advanced prostate cancer therapy settings will boost sales of PARP indicators in the sector.

The North America PARP Inhibitors market holds a significant regional revenue share.

The North America PARP Inhibitors market is expected to register the highest market share in revenue in the near future due to the region's sophisticated healthcare sector and high healthcare spending. The rising incidence of solid tumors in the areas and the availability of authorized PARP inhibitors are two major drivers of the market's expansion. The region's demand for PARP inhibitors is anticipated to grow throughout the forecast period due to new product launches, the presence of major market players who place a high priority on R&D, and an increase in cancer incidence. In addition, Asia Pacific is projected to grow rapidly in the global PARP Inhibitors market due to the growing population. The Asia Pacific market is anticipated to grow faster due to rising research and development activities and increasing healthcare spending. The market for PARP inhibitors is projected to continue to grow due to investments made by major companies in emerging nations to fill unmet demands and improve their competitive position.

Competitive Landscape

Some major key players in the PARP Inhibitors market are AstraZeneca, GlaxoSmithKline, Merck Co. & Inc, GlaxoSmithKline plc, AbbVie Inc, Clovis Oncology, Medivation, Johnson & Johnson Services, Inc, Pfizer Inc., Repare Therapeutics, Inc., Genentech, Inc., Artios Pharma, Repare Therapeutics Inc., Sierra Oncology, Inc., KaryopharmTherapeutics Inc., Ono Pharmaceutical Co., Ltd. and Jiangsu Hengrui Medicine Co., Ltd.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global PARP Inhibitors Market Snapshot

Chapter 4. Global PARP Inhibitors Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Drug Type Estimates & Trend Analysis

5.1. by Drug Type & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Drug Type:

5.2.1. Olaparib

5.2.2. Niraparib

5.2.3. Rucaparib

5.2.4. Talazoparib

Chapter 6. Market Segmentation 2: by Indication Estimates & Trend Analysis

6.1. by Indication & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Indication:

6.2.1. Ovarian Cancer

6.2.2. Breast Cancer

6.2.3. Prostate Cancer

6.2.4. Pancreatic Cancer

Chapter 7. Market Segmentation 3: by Distribution Channel Estimates & Trend Analysis

7.1. by Distribution Channel & Market Share, 2019 & 2030

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Distribution Channel:

7.2.1. Hospital Pharmacies

7.2.2. Retail Pharmacies

7.2.3. Online Pharmacies

Chapter 8. PARP Inhibitors Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America PARP Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2022-2030

8.1.2. North America PARP Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2022-2030

8.1.3. North America PARP Inhibitors Market revenue (US$ Million) by Distribution Channel, 2022-2030

8.1.4. North America PARP Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

8.2. Europe

8.2.1. Europe PARP Inhibitors Market revenue (US$ Million) by Drug Type, 2022-2030

8.2.2. Europe PARP Inhibitors Market revenue (US$ Million) by Indication, 2022-2030

8.2.3. Europe PARP Inhibitors Market revenue (US$ Million) by Distribution Channel, 2022-2030

8.2.4. Europe PARP Inhibitors Market revenue (US$ Million) by country, 2022-2030

8.3. Asia Pacific

8.3.1. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by Drug Type, 2022-2030

8.3.2. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by Indication, 2022-2030

8.3.3. Asia-Pacific PARP Inhibitors Market revenue (US$ Million) by Distribution Channel, 2022-2030

8.3.4. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by country, 2022-2030

8.4. Latin America

8.4.1. Latin America PARP Inhibitors Market revenue (US$ Million) by Drug Type, 2022-2030

8.4.2. Latin America PARP Inhibitors Market revenue (US$ Million) by Indication, 2022-2030

8.4.3. Latin America PARP Inhibitors Market revenue (US$ Million) by Distribution Channel, 2022-2030

8.4.4. Latin America PARP Inhibitors Market revenue (US$ Million) by country, 2022-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa PARP Inhibitors Market revenue (US$ Million) by Drug Type, 2022-2030

8.5.2. Middle East & Africa PARP Inhibitors Market revenue (US$ Million) by Indication, 2022-2030

8.5.3. Middle East & Africa PARP Inhibitors Market revenue (US$ Million) by Distribution Channel, 2022-2030

8.5.4. Middle East & Africa PARP Inhibitors Market revenue (US$ Million) by country, 2022-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles 

9.2.1. AstraZeneca

9.2.2. GlaxoSmithKline

9.2.3. Merck Co. & Inc

9.2.4. GlaxoSmithKline plc

9.2.5. AbbVie Inc

9.2.6. Clovis Oncology

9.2.7. Medivation

9.2.8. Johnson & Johnson Services, Inc

9.2.9. Pfizer Inc.

9.2.10. Repare Therapeutics, Inc.

9.2.11. Genentech, Inc.

9.2.12. Artios Pharma

9.2.13. Repare Therapeutics Inc.

9.2.14. Sierra Oncology, Inc.

9.2.15. KaryopharmTherapeutics Inc.

9.2.16. Ono Pharmaceutical Co., Ltd.

9.2.17. Jiangsu Hengrui Medicine Co., Ltd.

9.2.18. Other Prominent Players

By Drug Type-

  • Olaparib
  • Niraparib
  • Rucaparib
  • Talazoparib

By Indication-

  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer
  • Pancreatic Cancer

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Our Clients

Media Citations

Growth opportunities and latent adjacency in

Select Licence Type
Related Reports

    A PHP Error was encountered

    Severity: Notice

    Message: Undefined variable: category

    Filename: user/report_list.php

    Line Number: 611

    Backtrace:

    File: /home/z8nbkwptb7pj/public_html/application/views/user/report_list.php
    Line: 611
    Function: _error_handler

    File: /home/z8nbkwptb7pj/public_html/application/views/user/user_layout.php
    Line: 6
    Function: view

    File: /home/z8nbkwptb7pj/public_html/application/controllers/User.php
    Line: 374
    Function: view

    File: /home/z8nbkwptb7pj/public_html/index.php
    Line: 315
    Function: require_once

    A PHP Error was encountered

    Severity: Notice

    Message: Trying to get property 'cat_id' of non-object

    Filename: user/report_list.php

    Line Number: 611

    Backtrace:

    File: /home/z8nbkwptb7pj/public_html/application/views/user/report_list.php
    Line: 611
    Function: _error_handler

    File: /home/z8nbkwptb7pj/public_html/application/views/user/user_layout.php
    Line: 6
    Function: view

    File: /home/z8nbkwptb7pj/public_html/application/controllers/User.php
    Line: 374
    Function: view

    File: /home/z8nbkwptb7pj/public_html/index.php
    Line: 315
    Function: require_once

  • Global Filgrastim Biosimilars Market
  • Global Spirulina Beverages Market
  • Large Tow Carbon Fiber Market Size, Share & Trends Analysis Report By End-Use (Aerospace, Energy, Au...
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals
Review Request

We’ll review your request & send a personalized quote for cost and time needed
Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..

Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.

Category
Quick Links
Office Address